The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

Group chairs propose funding strategy to jump-start correlative studies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.” 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Peter J. O'Dwyer, MD
Group co-chair, ECOG-ACRIN Cancer Research Group; Professor of medicine (hematology-oncology), Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
By Jeff Sorenson
In Brief

UCLA researchers receive $7M NIH grant to launch trial for immunotherapy-related diabetes

UCLA researchers have received a grant worth up to $7 million over five years from the National Institute of Allergy and Infectious Diseases to launch a first-in-human clinical trial evaluating whether drugs already used to treat autoimmune diseases can prevent or reverse immune checkpoint inhibitor-induced type 1 diabetes, a rare but often permanent complication of cancer immunotherapy.
Byline
Peter J. O'Dwyer, MD
Group co-chair, ECOG-ACRIN Cancer Research Group; Professor of medicine (hematology-oncology), Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account